49 results about "Stem-cell therapy" patented technology

The invention relates to the technical field of curative effect prediction, in particular to a curative effect prediction method and system for treating spinal cord injury by stem cells, and the method comprises the following steps: obtaining a multi-parameter metabolism sequence and constructing an activation rhythm map, recognizing a neural restoration synchronization section, extracting a metabolism dominant path and evaluating electrical signal response, generating a para-position map layer and predicting a curative effect trend. According to the method, through introduction of cross-time-sequence metabolism and trend synchronous identification of electrophysiological indexes, dynamic mapping of stem cell activation rhythms is realized, neural axon morphological changes and cerebrospinal fluid metabolism parameters are linked, and distribution positions of key response points in a treatment cycle are determined; the method comprises the following steps: establishing a causal path based on a sequence of metabolic mutation and neural restoration events, extracting an evolution stage dominated by a metabolic driving effect, marking a matching trend of a curative effect response and an intervention path on a time axis, identifying the number and positions of trend convergence, withdrawal and interruption areas, and realizing collaborative prediction of a restoration progress and a curative effect trend.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

The invention discloses a surface-enhanced Raman probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical imaging and stem cell therapy. The preparation method comprises the following steps: coating an ultrathin silver shell layer on the surface of gold nanoparticles to obtain Au-coated Ag particles; 4-sulfydryl phenylboronic acid pinacol ester molecules are modified on the surface of Au (at) Ag to form a Raman report layer, then sulfydryl-polyethylene glycol is introduced to realize biological orthogonal coupling, and the modified SERS probe is obtained through bovine serum albumin modification; jointly incubating the modified SERS probe and the azidation-labeled mouse bone marrow mesenchymal stem cells, so as to form an mmol / LSC-SERS composite probe; the obtained probe has good biocompatibility, stability and anti-interference capability and is suitable for a complex physiological environment, and the preparation method is simple and good in repeatability, is completely carried out in a water phase and does not need an organic solvent.

The invention provides a method for producing functional spinal cord GABAergic neural precursor cells from human pluripotent stem cells, which successfully realizes directional differentiation of the human pluripotent stem cells by adopting a feeder-layer-free culture method based on a three-stage in-vitro induced differentiation strategy. The invention further provides application of the cells obtained through the method in treatment of spinal cord injury, a novel strategy based on the functional spinal cord GABAergic neural precursor cells is provided, a new thought and means are provided for treatment of spinal cord injury, and stem cell treatment is expected to proceed towards clinical precision and industrial application.

The present invention relates to the field of stem cell technology and specifically discloses an application of mesenchymal stem cells (MSCs) for the treatment of lower extremity venous ischemia. This application involves pre-treating human mesenchymal stem cells (hMSCs) with the SDF1-FGF2 fusion protein. This pre-treatment significantly enhances the cell viability, blood flow recovery, and anti-inflammatory effects of hMSCs in a lower extremity venous ischemia model. When hMSCs pre-treated with SDF1-FGF2 were injected into mice modeling venous ischemia, they demonstrated superior effects compared to untreated cells in improving blood perfusion, reducing inflammatory responses, and restoring motor function. This method provides a highly effective stem cell therapy strategy for vascular diseases such as lower extremity venous ischemia.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

A silicon-anchored hardware enforcement system enables low-latency, cryptographically gated execution of artificial intelligence for stem cell therapy and regenerative medicine. A Sovereign Identity Token derived from a Physical Unclonable Function (PUF) permanently binds model decryption to a specific hardware instance and restricts execution to a Trusted Execution Environment synchronized to a hardware-protected Safety Epoch. Encrypted AI model weights are decryptable only upon successful hardware validation. Multimodal clinical inputs, including genetic, imaging, and structured patient data, are integrated through a hardware-constrained fusion architecture that operates under enforced biological safety parameters. FPGA-implemented predicate logic evaluates defined biological safety conditions at sub-millisecond latency, and an ASIC-based nullification circuit irreversibly suppresses outputs that violate hardware-defined thresholds within a bounded millisecond response time. A distributed revocation protocol propagates credential invalidation across networked nodes within sub-second latency while preserving reduced-capacity safe mode operation. A permissioned provenance ledger records hardware-attested execution events and supports automated regulatory documentation. The system provides secure clinical deployment, federated research enablement, and verifiable auditability for high-risk therapeutic environments.

The utility model discloses a cell culture detection box for stem cell treatment, and relates to the technical field of cell culture. The detection device comprises a detection box body, a mounting plate is arranged in the detection box body, a plurality of fixing grooves are formed in the mounting plate, a two-way screw rod is rotationally matched in the fixing grooves, a connecting rod is arranged at one end of the two-way screw rod, a handle is arranged at one end of the connecting rod, two moving blocks are in threaded fit with the two-way screw rod, and connecting plates are arranged on the moving blocks. And an elastic piece is arranged on one side of the connecting plate. According to the culture dish fixing device, the arc-shaped fixing plates located on the two moving blocks can be driven to move oppositely under the rotation of the two-way lead screw, so that the culture dishes can be fixed, and when the culture dishes with different sizes are fixed under the arrangement of the elastic pieces, the culture dishes can be fixed more conveniently. The culture dish is further fixed through the pressure of the elastic piece, so that the culture dish can be fixed more stably.

The present disclosure provides for a method of characterizing a nucleic acid network comprising: providing a biological sample on a substrate, wherein the biological sample comprises the nucleic acid network; applying spatially-aware graph neural networks (spaGNN) to the biological sample to obtain characterization data; and analyzing the characterization data. Also provided herein is a method of providing stem cell therapy to a subject in need thereof comprising: performing the method disclosed herein to a stem cell; and administering the stem cell to the subject. Further disclosed herein is a kit comprising a stem cell targeting reagent and an organelle map, wherein the organelle map comprises data indicating identification and proximity of RNA inside of an organelle and outside of an organelle.

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

The invention relates to a method for regulating osteogenic differentiation of periodontal ligament stem cells in an inflammatory microenvironment based on a stem cell-derived extracellular matrix. The method comprises the following steps: 1) separating and identifying bone marrow cells BMCs and periodontal ligament cells PDLCs; (2) preparing a bone marrow stem cell derived extracellular matrix B-ECM and a periodontal ligament stem cell derived extracellular matrix P-ECM; 3) intervening PDLSCs in an inflammation microenvironment by using the B-ECM and the P-ECM obtained in the step 2), and 4) performing animal experiment.The adverse effect of inflammation on the osteogenic differentiation capacity of periodontal ligament stem cells in the stem cell treatment process is reversed, so that a basis is provided for developing a novel periodontitis regeneration treatment strategy based on an ECM stent.

The invention discloses a bispecific antibody-UC-MSCs preparation for targeting prostate diseases as well as preparation and application of the bispecific antibody-UC-MSCs preparation. The preparation comprises a bispecific antibody BsAb-1 and human umbilical cord mesenchymal stem cells (UC-MSCs), the BsAb-1 is formed by connecting an anti-CD105 single-domain antibody, an anti-PSCA single-domain antibody and a flexible peptide linker in series, wherein the amino acid sequence of the BsAb-1 is as shown in SEQ ID NO: 4. According to the preparation, the UC-MSCs are delivered to a prostate focus through the targeting bridge effect of BsAb-1, the focus enrichment amount within 72 hours is increased by 6.3 times compared with that of pure UC-MSCs, and meanwhile retention of non-target organs such as the liver and the spleen is reduced. The preparation can effectively relieve inflammatory response and fibrosis of chronic prostatitis, and the curative effect of the preparation is remarkably superior to that of pure UC-MSCs treatment. Precise targeted treatment of prostate diseases is achieved, the curative effect is remarkably better than that of a traditional stem cell therapy method, and high clinical application value is achieved.

The present disclosure describes electrically stimulating biological systems using meshes, wherein the mesh comprises nanoscale wires and / or nanoelectronics. These may be embedded as a scaffold in biological structures, such as tissues, organoids, organs, organisms, and the like. These may be connectable to an external device to determine a property of the scaffold and / or to apply a stimulus to the biological structure. Certain embodiments are Al-driven systems designed for applications such as drug screening, stem cell therapy, or the like. In addition, some embodiments are directed to predictive models that can be used to predict and / or control the biological structure. For example, certain cells may be caused to mature more quickly, and / or the functionality of the biological structure may be enhanced or inhibited by using such models to apply suitable electrical stimuli to the biological structure, and / or portions of the biological structure.

The invention relates to a biological value method for evaluating the inflammation inhibition function of mesenchymal stem cells, and belongs to the technical field of stem cell treatment and biological evaluation of inflammatory diseases. The method provided by the invention has high sensitivity, high specificity and good repeatability, and is suitable for the titer evaluation of MSCs in the treatment of various inflammatory diseases. By introducing an IFNGR1 molecular index and a quantitative threshold judgment standard, a standardized and high-efficiency evaluation system from an evaluation mode depending on a'complex function experiment 'to a'molecular detection' is realized, and an innovative solution is creatively provided for standardized evaluation of the MSCs inflammation inhibition titer.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

This invention belongs to the field of cell culture technology, specifically relating to a method for preparing 3D hybrid cell microspheres and their applications. The invention involves co-seeding olfactory mucosal basal stem cells and olfactory mucosal mesenchymal stem cells in a low-absorption culture plate to obtain 3D hybrid cell microspheres. In the 3D hybrid culture system, the two cell types provide support for the state of the olfactory mucosal basal stem cells and olfactory mucosal mesenchymal stem cells, mutually supporting each other and further enhancing their biological characteristics, making them easier to colonize at lesion sites, thereby improving the anti-apoptotic ability of the 3D hybrid cell microspheres. The 3D hybrid cell microspheres prepared by this method offer promising applications for stem cell therapy of respiratory diseases and provide a foundation for using olfactory mucosal-derived stem cells in regenerative medicine.

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

The present application relates to a kind of mesenchymal stem cells of overexpressing HDAC9 and its preparation method and application, belong to stem cell therapy technical field.The present application overexpressing HDAC9 mesenchymal stem cell includes the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:2 and dCas9-target plasmid.The present application constructs MSCs of HDAC9 gene modification for the first time, improves its inhibition effect to immune inflammation, so as to promote its treatment effect in immune inflammation.

This invention discloses a neutral homogeneous polysaccharide from Rehmannia glutinosa, its preparation method, and its applications, belonging to the field of traditional Chinese medicine preparation technology. The polysaccharide is mainly composed of galactose, glucose, and fructose in a molar ratio of 2.72:1.17:1.11, with a weight-average molecular weight of 2152 Da. The neutral polysaccharide from Rehmannia glutinosa can exert a therapeutic effect on osteoporosis by increasing bone mineralization and bone density; it can also promote the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), showing significant application effects in the preparation of stem cell therapy drugs for bone defects. The neutral homogeneous polysaccharide from Rehmannia glutinosa shows great application potential in the preparation of drugs for treating osteoporosis and as a stem cell therapy (especially bone regeneration therapy based on bone marrow mesenchymal stem cells). This provides new candidate substances and research directions for developing efficient and safe treatment strategies for bone metabolic diseases derived from traditional Chinese medicine.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

The invention relates to bioinformatics technology and specifically to an analysis method of a spatial transcriptome-based 4D-printed stem cell scaffold for enhancing diabetic skin injury healing. Spatial transcriptome sequencing is performed on tissues from both the PBS group and the combined treatment group. Cell clustering and annotation identify main cell types, followed by visualization of their spatial distributions in both groups. The proportions of various cell types are statistically quantified and plotted. Cell subsets exhibiting significant differential gene expression are enriched and verified. Using a 4D-printed stem cell scaffold combined with a piRNA inhibitor and stem cell therapy, the method reveals spatial distribution and dynamic cellular changes during wound healing. It identifies precise cellular locations and gene expression patterns within tissues, providing critical insights into the biological processes by which biomaterials promote diabetic injury repair. This approach offers new directions for future drug development.

This invention discloses a stem cell preparation for septic cardiomyopathy that targets and regulates LCN2, and its preparation method, belonging to the field of biomedical technology. Addressing the technical problems of insufficient targeting, weak LCN2 regulation, and limited efficacy in treating septic cardiomyopathy associated with traditional umbilical cord mesenchymal stem cell preparations in the prior art, this invention provides a stem cell preparation for septic cardiomyopathy that targets and regulates LCN2, and its preparation method. Using umbilical cord mesenchymal stem cells as a carrier, it achieves precise intervention on LCN2, enhances the repair capacity of umbilical cord mesenchymal stem cells for septic myocardial damage, and provides a new stem cell therapy option for septic cardiomyopathy that is highly targeted, has definite efficacy, and is highly safe.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

The invention belongs to the technical field of stem cell treatment, and discloses a traditional Chinese medicine extract for improving the homing ability of mesenchymal stem cells and application thereof.After a beautiful millettia root extract obtained through simple water extraction and umbilical cord mesenchymal stem cells are subjected to mixed culture, the migration and / or homing ability of the obtained umbilical cord mesenchymal stem cells is remarkably improved, and the homing ability of the umbilical cord mesenchymal stem cells is improved. Therefore, the beautiful millettia root extract can be used for preparing a preparation for improving migration and / or homing of the umbilical cord mesenchymal stem cells. Through cell tests, it is studied that the beautiful millettia root extract does not have obvious cytotoxicity to umbilical cord mesenchymal stem cells and does not change functions and phenotypes of the umbilical cord mesenchymal stem cells, and therefore the beautiful millettia root extract can be used as a natural extract for improving the treatment capacity of the umbilical cord mesenchymal stem cells. The invention further researches the application effect of the umbilical cord mesenchymal stem cells subjected to mixed culture pretreatment of the beautiful millettia root extract, and when the umbilical cord mesenchymal stem cells are applied to scalded wounds of mice, the wound treatment and healing capabilities of the umbilical cord mesenchymal stem cells can be remarkably improved.

This invention provides a manganese-containing stem cell coating with anticoagulant function, its preparation method, and its application, belonging to the field of stem cell therapy technology. The preparation method includes the following steps: tannic acid, MnCl2·4H2O, and sodium heparin are simultaneously added to a mesenchymal stem cell suspension, mixed, incubated, and centrifuged to obtain an incubated stem cell solution. The precipitate is collected to obtain a manganese-containing stem cell coating with anticoagulant function. This invention uses a mixture of natural tannic acid and manganese chloride tetrahydrate, which can deposit on a thin film on the surface of mesenchymal stem cells. Furthermore, the coating, carrying sodium heparin, can effectively prevent coagulation reactions caused by stem cells. Results show that the manganese-containing stem cell coating with anticoagulant function of this invention has a significant antithrombotic effect. In addition, this coating retains the original activity of stem cells, has good biocompatibility, and significantly improves the therapeutic effect of ulcerative colitis, thus making stem cell therapy safe and effective.

The invention relates to a Raman spectrum biochemical component decomposition and mixing method based on a depth automatic encoder and self-adaptive spectrum shift, which comprises the following steps: acquiring Raman spectrum of a single cell, and constructing a data set; the data set is preprocessed; constructing a deep automatic encoder neural network model, and training the deep automatic encoder neural network model by using the preprocessed data set; wherein the deep automatic encoder neural network model comprises a feature extraction encoder and a spectrum reconstruction decoder; and performing biochemical component decomposition and mixing of the Raman spectrum by using the trained deep automatic encoder neural network model. According to the invention, component characteristics can be automatically extracted from a complex Raman spectrum, high-precision, dynamic and interpretable unmixing analysis is realized, and an innovative tool is provided for automatic production and real-time quality control of stem cell treatment products.